Trial
NCT00543114
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Dana-Farber Cancer Institute
Collaborators
Brigham and Women's Hospital; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Celgene Corporation
Condition
Chronic Lymphocytic Leukemia
Intervention
Lenalidomide
Why stopped
lack of efficacy and tolerability
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-05-27